| Bioactivity | VK3-OCH3 is a potent antitumor agent. VK3-OCH3 shows cytotoxicity for neuroblastoma cell lines and low cytotoxicity for normal cell lines. VK3-OCH3 induces apoptosis and cell cycle arrest at G2/M phase in IMR-32 cells. VK3-OCH3 shows antitumor activity[1]. |
| Invitro | VK3-OCH3 (compound 5) shows cytotoxicity with IC50s of 2.43, 1.55, 10.69, 3.45, 26.24, 87.11 µM for IMR-32, LA-N-1, NB-39, SK-N-SH, HUVEC, HDF cells, respectively[1].VK3-OCH3 (1, 3, 10 µM) induces apoptosis and cell cycle arrest at G2/M phase in IMR-32 cells[1].VK3-OCH3 (0-48 h) increases the expression of HO-1 in 8~24 h, and Caveolin-1 in 48 h in IMR-32 and LA-N-1 cells[1].VK3-OCH3 (0-48 h) increases the expression of phospho-p38-MAPK and decreases the expression of p21 and clusterin[1]. |
| Name | VK3-OCH3 |
| CAS | 255906-59-3 |
| Formula | C14H14O3S |
| Molar Mass | 262.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kitano T, et al. Vitamin K3 analogs induce selective tumor cytotoxicity in neuroblastoma. Biol Pharm Bull. 2012;35(4):617-23. |